// App-Quantinova.ai

P1103 : INMIND: A PHASE 3 STUDY OF TAFASITAMAB PLUS LENALIDOMIDE AND RITUXIMAB VERSUS PLACEBO PLUS LENALIDOMIDE AND RITUXIMAB FOR RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (FL) OR MARGINAL ZONE LYMPHOMA (MZL)

Researchers

Presenter

  • Laurie H. Sehn

Principal Investigators

  • Kai Hbel

  • Stefano Luminari

  • Antonio Salar

  • Bj�rn E. Wahlin

  • Ajay K. Gopal

  • Christophe Bonnet

  • Shankara Paneesha

  • Marek Trneny

  • Hafsat Mashegu

  • Christine Lihou

  • Di Li

  • Christian W. Scholz

Medical Centers

  • Clinical Hematology,Centre Hospitalier Universitaire, University of Liège,Liège,Belgien

  • Department of Hematology, Hospital del Mar, Barcelona, Spain

  • Division of Medical Oncology,University of Washington Medicine,Seattle,États-unis

  • University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom

  • Department of Hematology, Hospital del Mar, Barcelona, Spain

  • Incyte Corporation,Wilmington, DE,Stati Uniti

  • BC Cancer Centre for Lymphoid Cancer and University of British Columbia, Vancouver, BC, Canada

  • Department of Medicine, Unit of Hematology,Karolinska Institute,Stockholm,Suède

  • Department of Hematology, Hospital del Mar, Barcelona, Spain

  • BC Cancer Centre for Lymphoid Cancer and University of British Columbia, Vancouver, BC, Canada

  • First Department of Medicine, First Faculty of Medicine,Charles University, General Hospital,Prague,Rep. Ceca

  • Incyte Corporation,Wilmington, DE,États-unis

  • First Department of Medicine, First Faculty of Medicine,Charles University, General Hospital,Prague,Rep. Ceca

  • BC Cancer Centre for L

  • Department of Internal Medicine I Oncology and Hematology,University Hospital Cologne,Cologne,Germania

  • Hematology Unit,Azienda USL-IRCCS di Reggio Emilia,Reggio Emilia,Italia

  • Department of Internal Medicine I Oncology and Hematology,University Hospital Cologne,Cologne,Germania

  • University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom

  • Clinical Hematology,Centre Hospitalier Universit

  • University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom

  • Department of Medicine, Unit of Hematology,Karolinska Institute,Stockholm,Suède

  • Department of Medicine, Rheumatology Unit, Karolinska Institute, Stockholm, Sweden

  • Department of Hematology and Oncology,Vivantes Klinikum Am Urban,Berlin,Deutschland

  • Hematology Unit,Azienda USL-IRCCS di Reggio Emilia,Reggio Emilia,Italia

  • Clinical Hematology,Centre Hospitalier Universitaire, University of Liège,Liège,Belgien

  • Department of Internal Medicine I Oncology and Hematology,University Hospital Cologne,Cologne,Germania

  • Division of Medical Oncology, University of Washington, Seattle, WA

  • Division of Medical Oncology,University of Washington Medicine,Seattle,États-unis

  • Department of Hematology and Oncology,Vivantes Klinikum Am Urban,Berlin,Deutschland

  • Incyte Corporation,Wilmington,Verenigde Staten

  • Department of Hematology and Oncology,Vivantes Klinikum Am Urban,Berlin,Deutschland

  • Department of Hematology and Oncology,Vivantes Klinikum Am Urban,Berlin,Deutschland

  • Department of Hematology, Hospital del Mar, Barcelona, Spain

  • Clinical Hematology,Centre Hospitalier Universitaire, University of Liège,Liège,Belgien

  • Division of Medical Oncology,University of Washington Medicine,Seattle,États-unis

  • First Department of Medicine, First Faculty of Medicine,Charles University, General Hospital,Prague,Rep. Ceca

  • Department of Hematology, Hospital del Mar, Barcelona, Spain

  • University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom

  • Department of Medicine, Unit of Hematology,Karolinska Institute,Stockholm,Suède

  • Univer

  • Hematology Unit,Azienda USL-IRCCS di Reggio Emilia,Reggio Emilia,Italia

  • Incyte Corporation,Wilmington, DE,Estados Unidos

  • Hematology Unit,Azienda USL-IRCCS di Reg

  • Hematology Unit,Azienda USL-IRCCS di Reggio Emilia,Reggio Emilia,Italia

  • Department of Medicine, Rheumatology Unit, Karolinska Institute, Stockholm, Sweden

  • Incyte Corporation, Wilmington, DE

  • Clinical Hematology,Centre Hospitalier Universitaire, University of Liège,Liège,Belgien

  • Department of Hematology and Oncology,Vivantes Klinikum Am Urban,Berlin,Deutschland

  • Departme

  • Division of Medical Oncology,University of Washington Medicine,Seattle,États-unis

  • Incyte Corporation,Wilmington, DE,Verenigde Staten

  • Incyte Corporation,Wilmington,Verenigde Staten

  • Department of Internal Medicine I Oncology and Hematology,University Hospital Cologne,Cologne,Germania

  • First Department of Medicine, First Faculty of M

  • University Hospitals Birmingham NHS Foundation Trust,Birmingham,Royaume-uni

  • Department of Hematology, Hospital del Mar, Barcelona, Spain

Locations

  • Canada

  • United States

  • Italy

  • Venezuela

  • Spain

  • Sweden

  • Belgium

  • United Kingdom

  • Czech Republic

  • Turkey

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

  • Oncology (ONC)

Disease

  • Congestive heart failure

  • Mucosa-associated lymphoid tissue lymphoma

  • Follicular lymphoma

  • CNS lymphoma

  • Lymphomas

Biomarkers

  • Creatinine

Drug/Treatment

  • Lenalidomide

  • Tafasitamab

  • Rituximab

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

Phase

  • III

Study Id's

  • NCT01685008

  • NCT02399085

  • NCT04680052

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved